Weidong Wendy

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann et al. · Leukemia · 2018 · 489 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results

Jörge E. Cortes, Benjamin D. Smith, Eunice S. Wang et al. · American Journal of Hematology · 2018 · 114 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

Michael R. Savona, Daniel A. Pollyea, Wendy Stock et al. · Clinical Cancer Research · 2018 · 107 citations · Full text

Medicine, Oncology, Pharmacology +16

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Michael Heuser, B. Douglas Smith, Walter Fiedler et al. · Annals of Hematology · 2021 · 53 citations · Full text

Medicine, Oncology, Pharmacology +12

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

Aaron H. Burstein, Qinying Zhao, Joel Ross et al. · Clinical Neuropharmacology · 2013 · 51 citations

Medicine, Pharmacokinetics, Pharmacology +17